VEEVHealthcare · Health Information ServicesThe 29 Wall Street analysts covering Veeva Systems, Inc. hold a median 12-month price target of $300 — +0.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Veeva Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Value (48): The shares cost a lot relative to the profits and assets behind them.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VEEV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +0.9% from it.
Of the 20 most recent actions, 18 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | Citigroup | Maintains | Neutral | $190 → $273 |
| 27 Aug 2026 | Baird | Maintains | Outperform | $260 → $300 |
| 27 Aug 2026 | Barclays | Maintains | Overweight | $275 → $315 |
| 27 Aug 2026 | BMO Capital | Maintains | Market Perform | $175 → $270 |
| 27 Aug 2026 | Canaccord Genuity | Maintains | Hold | $220 → $260 |
| 27 Aug 2026 | Evercore ISI Group | Maintains | In-Line | $185 → $250 |
| 27 Aug 2026 | Guggenheim | Maintains | Buy | $276 → $310 |
| 27 Aug 2026 | Mizuho | Maintains | Outperform | $270 → $280 |
| 27 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $215 → $275 |
| 27 Aug 2026 | Needham | Maintains | Buy | $270 → $310 |
| 27 Aug 2026 | Piper Sandler | Maintains | Overweight | $295 → $320 |
| 27 Aug 2026 | RBC Capital | Maintains | Outperform | $275 → $325 |
| 27 Aug 2026 | TD Cowen | Maintains | Buy | $235 → $283 |
| 27 Aug 2026 | Truist Securities | Maintains | Buy | $262 → $305 |
| 27 Aug 2026 | UBS | Maintains | Neutral | $190 → $290 |
| 24 Aug 2026 | Needham | Reiterates | Buy | $270 |
| 24 Aug 2026 | Piper Sandler | Assumes | Overweight | $235 → $295 |
| 20 Aug 2026 | Guggenheim | Maintains | Buy | $232 → $276 |
| 20 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 18 Aug 2026 | Barclays | Maintains | Overweight | $235 → $275 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VEEV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Veeva Systems, Inc. returned +3.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 11% of US stocks
Cheaper than 15% of US stocks
Cheaper than 6% of US stocks
Higher than 66% of US stocks
Higher than 69% of US stocks
Higher than 87% of US stocks
Higher than 87% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Higher than 87% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Veeva Systems, Inc. has a market value of $47.9B and an enterprise value of $40.8B.
Revenue in the twelve months to 31 July 2026: $3.5B. The latest quarter grew 17.6% year on year.
Net income over the same four quarters: $1.0B, a 29.3% net margin.
Diluted earnings per share, trailing twelve months: $6.08.
Free cash flow in the twelve months to 31 July 2026: $1.7B.
Trailing P/E: 48.4×; forward P/E: 28.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Veeva Systems, Inc. employs 7,928 people — $436K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veeva Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Veeva Systems will host its investor day virtually on Thursday, November 5, 2026.
Why it matters — VEEV watchers may note the scheduled opportunity to hear from the company at its investor day.
Veeva expanded its partnership with IQVIA through a clinical operations software suite, supporting wider adoption and integrated workflows.
Why it matters — The expanded partnership may broaden Veeva's market reach and growth prospects, according to the excerpt.
Veeva Systems (VEEV) closed at $301.63 on the latest trading day, up 1.95% from its prior close.
Why it matters — The update reports a gain in VEEV shares on the latest trading day.
Veeva Systems' Basics product has gained traction with more than 175 emerging biotech firms. The excerpt says its streamlined software is intended to simplify drug development processes.
Why it matters — Adoption among early-stage biotech firms could create long-term revenue opportunities for Veeva.
IQVIA selected Veeva clinical operations applications. The excerpt provides no further details about the selection.
Why it matters — The selection is relevant to VEEV watchers as an adoption of Veeva’s clinical operations applications by IQVIA.
The 29 Wall Street analysts covering Veeva Systems, Inc. have a median 12-month price target of $300, with estimates ranging from $180 to $343. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Veeva Systems, Inc., 20 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Veeva Systems, Inc. 81 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Veeva Systems, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +0.9% from the last close, and Ticker Nerd's factor model ranks Veeva Systems, Inc. 81 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veeva Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VEEV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $180 to $343 over the next 12 months.
Veeva Systems, Inc. returned +3.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Veeva Systems Inc. is a cloud software company that provides industry-specific solutions for the global life sciences sector.
The most recent item we track (PRNewsWire, 14 Oct 2026): "Veeva to Host Virtual Investor Day on November 5, 2026". Veeva Systems will host its investor day virtually on Thursday, November 5, 2026.
Veeva Systems Inc. is a cloud software company that provides industry-specific solutions for the global life sciences sector. Veeva Systems Inc. offers applications, data, and consulting services designed to support pharmaceutical, biotechnology, and medical device companies across research and development, quality, and commercial operations. Its product portfolio includes platforms for clinical, regulatory, quality, and field activities, along with customer relationship management, content management, analytics, and data services tailored to life sciences workflows. The company also delivers cloud-based tools that help organizations manage complex processes from drug development through commercialization. Veeva Systems Inc. plays a central role in the life sciences technology market by combining software and data in a specialized industry cloud built for highly regulated environments. Founded in 2007 and headquartered in Pleasanton, California, the company focuses on serving customers that need compliant, scalable digital systems for critical business functions.
CEO Mr. Peter P. Gassner · 7,928 employees · United States · https://www.veeva.com
